김현기 helped start Stone Bridge Ventures' biotech investing efforts after spending about 12 years working in R&D and global business development at Dong-A pharma affiliates, giving him hands-on experience in drug development before he became an investor. He's known for making an early, independent bet on Adel's tau-targeting approach to Alzheimer's when few others were investing, has published research and holds patents related to biologics manufacturing, and has talked about wanting to help build a major Korean biotech company while staying involved with the companies he backs even after he exits.